Advertisements


Why Tetraphase Pharmaceuticals Is Getting Cut in Half

Tetraphase Pharmaceuticals saw its shares get cut in half on Wednesday after the firm provided an update on its late-stage clinical trial for the treatment of urinary tract infections......»»

Category: blogSource: 247wallstFeb 14th, 2018

Why Tetraphase Pharmaceuticals Shares Are Popping

Tetraphase Pharmaceuticals saw its shares make a solid gain early on Wednesday after the company announced an exclusive licensing agreement in Asia......»»

Category: blogSource: 247wallstFeb 21st, 2018

Eldorado Gold, Teekay Tankers Dip into Tuesday’s 52-Week Low Club

Eldorado Gold, Teekay Tankers, Tetraphase Pharmaceuticals, and Ohr Pharmaceuticals all posted new 52-week lows Tuesday......»»

Category: blogSource: 247wallstFeb 20th, 2018

Treehouse Foods, Baker Hughes Sink into Thursday’s 52-Week Low Club

Treehouse Foods, CYS Investments, Baker Hughes, and Tetraphase Pharmaceuticals all posted new 52-week lows Thursday......»»

Category: blogSource: 247wallstFeb 15th, 2018

Market Movers Today: Tetraphase Pharmaceuticals Inc (TTPH), Twilio Inc (TWLO), Genesco Inc. (GCO), Nektar Therapeutics (NKTR), and More

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) (Benzinga) Tetraphase Pharmaceuticals Inc’s Ignite3 trial evaluating the company’s le.....»»

Category: topSource: insidermonkeyFeb 15th, 2018

Tetraphase Pharma, Tanger Dive into Wednesday’s 52-Week Low Club

Tetraphase Pharmaceuticals, Neovasc, Tanger Factory Outlet, and Baker Hughes all posted new 52-week lows Wednesday......»»

Category: blogSource: 247wallstFeb 14th, 2018

Tetraphase Pharma Shares Plunge After Antibiotic Fails Late-Stage Trial

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH)'s Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed Latest Ratings.....»»

Category: blogSource: benzingaFeb 14th, 2018

Mid-Day Market Update: U.S. Stocks Turn Higher; Tetraphase Pharmaceuticals Shares Plummet

Midway through trading Wednesday, the Dow traded up 0.17 percent to 24,682.01 while the NASDAQ climbed 0.79 percent to 7,069.26. The S&P also rose, gaining 0.39 percent to 2,673.45. read more.....»»

Category: blogSource: benzingaFeb 14th, 2018

Galmed Pharma"s stock loses more than half its value after drug trial misses endpoint

Shares of Galmed Pharmaceuticals Ltd. plunged 62% to pace all the premarket.....»»

Category: topSource: marketwatchFeb 14th, 2018

U.S. Biotech/Pharma Sector Daily Observations Letter: February 13, 2018 (Featuring Tetraphase Pharmaceuticals)

U.S. Biotech/Pharma Sector Daily Observations Letter: February 13, 2018 (Featuring Tetraphase Pharmaceuticals).....»»

Category: topSource: seekingalphaFeb 14th, 2018

Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements

WATERTOWN, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceut.....»»

Category: earningsSource: benzingaNov 2nd, 2017

Tetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst

Tetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst.....»»

Category: topSource: seekingalphaSep 16th, 2017

Tetraphase Pharmaceuticals (TTPH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow

Tetraphase Pharmaceuticals (TTPH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow.....»»

Category: topSource: seekingalphaSep 12th, 2017

Kala Pharma Has 2 Material Milestones Upcoming In Q4

Biotech traders are always on the lookout for stocks with major catalysts on the horizon, and newly-public Kala Pharmaceuticals Inc (NASDAQ: KALA) fits the mold ahead of what will be a critical second half o Latest Ratings for KALA D.....»»

Category: blogSource: benzingaAug 14th, 2017

Zynerba Shares Cut In Half After Phase 2 Trial Doesn"t Meet Primary Endpoint

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares are trading lower by $8.50, or 56 percent, at $6.50 in Monday's session. read more.....»»

Category: blogSource: benzingaAug 7th, 2017

Tetraphase Pharma Decides to Reap Profits With Secondary Offering

Tetraphase Pharmaceuticals saw its shares pull back on Friday after the company announced that it has priced a secondary offering......»»

Category: blogSource: 247wallstJul 28th, 2017

Why Tetraphase Pharmaceuticals Fell 11.7% Today

The company announced a stock offering that will bolster its balance sheet but also dilute current investors......»»

Category: topSource: foxnewsJul 27th, 2017

Here"s Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today

The company announced positive top-line results from a phase 3 trial, which means regulatory submissions are on the way......»»

Category: topSource: foxnewsJul 26th, 2017

Valeant Pharmaceuticals: The Fire Sale Continues

The beleaguered drug maker sold its Obagi Medical Products business for less than half hat t paid for the company four years ago......»»

Category: blogSource: barronsJul 17th, 2017

Bay Area biotech slashes half of staff after drug partnerships falter

Bay Area biotech OncoMed Pharmaceuticals will cut about half its staff in a bid to reduce costs, the company said Monday, after a series of stumbles in clinical trials left the firm struggling. Redwood City-based OncoMed said the roster reduction, whic.....»»

Category: topSource: bizjournalsApr 24th, 2017

Bay Area biotech slashes half of staff after drug partnerships falter

OncoMed Pharmaceuticals will cut about half its staff in a bid to reduce costs, the company said Monday, after a series of stumbles in clinical trials left the firm struggling. Redwood City-based OncoMed said the roster reduction, which will leave it w.....»»

Category: topSource: bizjournalsApr 24th, 2017